# Progress Note 04 — Sick Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pablo Neruda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML051-SYN-TD
- Date: 1971-08-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marisol Fairweather-Diaz, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Sick Visit
- Services: Problem-oriented office visit, established patient

## Chief complaint

Itchy rash for four days. **S**

## History of present illness

Mr. Neruda, a 67-year-old man with metastatic hormone-sensitive prostate cancer on leuprolide and apalutamide, now in the third week of radiotherapy to the prostate, called the clinic and was seen the same day, with a professional Spanish interpreter. Four days ago an itchy red rash appeared on his chest and spread to his back and upper arms. He has taken apalutamide for eight weeks. He started no other new medicine, soap or detergent. He has no fever, sore mouth, sore or red eyes, blisters, peeling, swelling of the face, or joint pain. The skin over the radiotherapy field on his lower abdomen is not affected. The itch keeps him awake for part of the night, but he is still writing every morning. **S**

| Element | Detail |
|---|---|
| Onset | Four days ago, eight weeks after starting apalutamide |
| Location | Chest, back and upper arms; face, palms, soles and the radiotherapy field spared |
| Character | Red, flat and slightly raised spots joining into patches; itchy |
| Associated signs and symptoms | Denies fever, mouth or eye sores, blisters, peeling and facial swelling |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or chills; tiredness from radiotherapy, unchanged |
| Integumentary | Positive | Itchy rash on the trunk and upper arms; no blisters or peeling |
| Eyes | Negative | No redness, pain or discharge |
| Ears, nose, mouth, and throat | Negative | No mouth sores or sore throat |
| Musculoskeletal | Negative | No joint pain or swelling; no bone pain |
| Genitourinary | Positive | Urinary frequency during radiotherapy, as expected; no burning or blood |

6 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet daily **S**
- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain **S**
- Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food **S**
- Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks **S**
- Cholecalciferol (vitamin D3) 1945 units (0.05 mg) oral tablet, one tablet daily **S**
- Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation **S**
- Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin) **S**
- Cetirizine 10 mg oral tablet, one tablet daily for itch **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/82 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.8 °C; oxygen saturation 97% on room air; weight 93 kg; BMI 29.4 kg/m². All vital signs are synthetic.

White cell count: 6.8 10*3/uL; Eosinophils: 0.3 10*3/uL; Creatinine: 0.97 mg/dL; eGFR (CKD-EPI 1966): 86 mL/min/1.73 m²; ALT: 27 U/L; AST: 26 U/L. All results are synthetic.

## Change since baseline

- White cell count: 6.4 10*3/uL at baseline, 6.8 10*3/uL at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 0.97 mg/dL at this visit **S**
- eGFR (CKD-EPI 1966): 87 mL/min/1.73 m² at baseline, 86 mL/min/1.73 m² at this visit **S**
- ALT: 22 U/L at baseline, 27 U/L at this visit **S**
- AST: 24 U/L at baseline, 26 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, comfortable; temperature 36.8, blood pressure 136/82, pulse 80 |
| Skin | Blanching erythematous macules and papules, merging into patches, over the chest, abdomen above the radiotherapy field, back and upper arms, about 20 percent of body surface; no vesicles, bullae, target lesions, skin pain or Nikolsky sign; face, palms, soles and genitals clear |
| Eyes | Conjunctivae clear |
| Mouth | Mucosa moist and intact; no ulcers |
| Lymph nodes | No cervical, axillary or inguinal lymphadenopathy |
| Abdomen | Soft and non-tender; no liver enlargement |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Apalutamide rash, grade 2** (L27.0). A maculopapular drug rash, a common effect of apalutamide, covering about 20 percent of the skin: grade 2 (10 to 30 percent). No features of a severe reaction: no mucosal sores, blisters or skin pain, no fever, no lymph nodes, eosinophils 0.3, and normal liver and kidney tests (ALT 27, AST 26, creatinine 0.97). Grade 2 rash does not require stopping apalutamide, and most such rashes settle on topical treatment. **S**
   - Continue apalutamide 240 mg daily.
   - Triamcinolone 0.1% cream twice daily for two weeks to the rash, not the face or groin, and a fragrance-free emollient.
   - Cetirizine 10 mg daily for itch.
   - Stop apalutamide and call the same day for blisters, peeling, mouth or eye sores, fever, or spread beyond a third of the skin.
   - Medical oncology informed today; radiotherapy continues.
2. **Metastatic hormone-sensitive prostate cancer** (C61). Third week of radiotherapy to the prostate; urinary frequency as expected; no bone pain. **S**
   - Three-month review as planned in five weeks.

## Medication changes

- Started: Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin) **S**
- Started: Cetirizine 10 mg oral tablet, one tablet daily for itch **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- ERLEADA (apalutamide) tablets: prescribing information (2026), Janssen Products, LP, via DailyMed (National Library of Medicine)

## Follow-up

- Nurse telephone call in three days, with a photograph of the rash through the patient portal if he wishes. Three-month review in five weeks. Same-day review for any of the warning signs. **S**
- Next scheduled visit 1971-09-14: three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year. **S**
